Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect
HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million People Infected, Including up to 4 Million in US
BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that the first patient was dosed in the global Phase 3 C-FORWARD trial evaluating the combination regimen of bemnifosbuvir and ruzasvir compared to the regimen of sofosbuvir and velpatasvir for the treatment of hepatitis C virus (HCV). C-FORWARD, the second of two Phase 3 trials comparing this regimen, is being conducted at study sites outside of North America. Atea initiated C-BEYOND, the Company's Phase 3 trial in the US and Canada in April 2025 and continues to enroll patients in that study. In both studies, the regimen of bemnifosbuvir and ruzasvir is being administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir is being administered orally once-daily for 12 weeks.
'We are pleased to reach another important milestone for our global HCV program with the first patient dosed in C-FORWARD, our HCV Phase 3 trial being conducted outside North America. Our Phase 3 program is now enrolling patients on a global basis,' said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and founder of Atea. 'We are focused on the successful development of a potential best-in-class HCV regimen that may make it easier to treat and cure patients infected with HCV. The target profile of our regimen is particularly well suited for both patients and healthcare providers in test-to-treat models of care, which enables seamless diagnosis and treatment for patients infected with HCV.'
HCV continues to be a significant global health burden despite the availability of direct-acting antivirals, with an estimated 50 million people worldwide chronically infected with HCV, and approximately one million new infections each year. It is estimated that between 2.4 to 4 million people in the US alone are living with chronic HCV.
'It has been nearly a decade since the last generation of treatments for HCV became available to patients and in this time, the patient population and what they need to obtain a cure has evolved. Many patients infected with HCV are taking concomitant medications, including some that may not be recommended with the currently available HCV therapies,' said Dr. Eric Lawitz, MD, The Texas Liver Institute, Clinical Professor of Medicine, University of Texas Health San Antonio. 'The regimen of bemnifosbuvir and ruzasvir may offer a potent and more convenient option for my patients and may also make treatment more accessible for any patient who tests positive for HCV. I look forward to seeing the Phase 3 results when they are available.'
'The evolving HCV patient population and rising burden of untreated HCV in Europe mirrors trends seen in North America. Many patients present with co-morbidities and complex medical histories, with treatment decisions often influenced by concomitant medications,' said Tarik Asselah, MD, PhD, a principal investigator in the C-FORWARD trial and a Professor of Hepatology, Hôpital Beaujon, Assistance Publique–Hôpitaux de Paris (AP-HP), University of Paris-Cité, France. 'To truly advance HCV eradication and meet the needs of today's patients, an ideal treatment would combine high efficacy, short duration, and minimal risk of drug-drug interactions."
Atea hosted a virtual HCV panel discussion with key opinion leaders (KOLs) on May 14, 2025. A panel of six experts, including leading hepatologists and prescribers from the US, Canada and Europe, discussed the current challenges for patients infected with HCV and the results from Atea's global Phase 2 study evaluating the regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor were reviewed. Company management also reviewed the HCV commercial market opportunity and the design for the global Phase 3 clinical development program. To listen to the replay of the KOL event, please click here.
About the Phase 3 C-BEYOND and C-FORWARD Trials in Adults with Chronic HCV
Atea is conducting two open-label Phase 3 trials, C-BEYOND in the US and Canada, and C-FORWARD, a global trial outside of North America. Each Phase 3 trial is expected to enroll approximately 880 treatment-naïve patients, including those with and without compensated cirrhosis. The trials are comparing the fixed dose combination (FDC) regimen of bemnifosbuvir and ruzasvir to the FDC regimen of sofosbuvir and velpatasvir. The regimen of bemnifosbuvir and ruzasvir is being administered orally once-daily for 8 weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis) while the regimen of sofosbuvir and velpatasvir is being administered orally once-daily for 12 weeks for all patients with or without compensated cirrhosis.
The primary endpoint for each trial is HCV RNA < lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment and encompasses sustained virologic response 12 weeks post-treatment (SVR12) in each arm. Measurement at 24 weeks from the start of treatment is to ensure the primary endpoint occurs at the same relative timepoint from the start of treatment in all patients.
Last month, at the European Association for the Study of the Liver (EASL) Congress 2025, Atea presented results from the full cohort of patients (n=275) enrolled in its Phase 2 study evaluating the regimen. These results showed a robust 98% (210/215) SVR12 with the regimen in the 'Per-Protocol Treatment-Adherent Population.' The SVR12 rate was 95% (245/259) in the 'Per-Protocol Regardless of Adherence Population' (also referred to as the 'efficacy evaluable population'), which included patients who were not treatment adherent (17%).
Results from three additional Phase 1 studies demonstrated that the combination of bemnifosbuvir and ruzasvir had a low risk of drug-drug interactions (DDIs) and supported the safety of the regimen in HCV patients co-infected with human immunodeficiency virus (HIV) taking a standard HIV treatment, and the safety of bemnifosbuvir in participants with hepatic or renal impairment with no need for dose adjustments.
About HCV
HCV is a blood-borne, positive-sense, single-stranded (ss) RNA virus that primarily infects liver cells. A leading cause of chronic liver disease and liver transplants, HCV is mainly spread via blood transfusion, hemodialysis and needle sticks, with 242,000 deaths occurring each year. Chronic HCV infection is the leading cause of liver cancer in the US, Europe and Japan.
In the US, HCV infections predominate in patients in the age group between 20-49 years old, and it is estimated that fewer than approximately 10% of patients have cirrhosis.
About Bemnifosbuvir and Ruzasvir for HCV
Bemnifosbuvir has been shown in in vitro studies to be approximately 10-fold more active than sofosbuvir (SOF) against a panel of laboratory strains and clinical isolates of HCV GT 1–5. In vitro studies have also demonstrated bemnifosbuvir remained fully active against SOF resistance-associated substitutions (S282T), with up to 58-fold more potency than SOF. The pharmacokinetic (PK) profile of bemnifosbuvir supports once-daily dosing for the treatment of HCV. In both nonclinical and clinical studies, bemnifosbuvir has been shown to have a low risk for DDIs. Bemnifosbuvir has been administered to over 2,300 subjects and has been well-tolerated at doses up to 550 mg for durations up to 12 weeks in healthy subjects and patients.
Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,100 subjects at daily doses of up to 180 mg for 12 weeks and has demonstrated a favorable safety profile. The PK profile of ruzasvir supports once-daily dosing.
About Atea Pharmaceuticals
Atea is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea's deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. Atea's lead program and current focus is on the development of the combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information, please visit www.ateapharma.com.
Forward Looking Statement
This press release includes 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the potential best-in-class profile of the regimen of bemnifosbuvir and ruzasvir for the treatment of HCV and the potential to develop a regimen that makes it easier to treat and cure HCV patients. When used herein, words including 'expected,' 'should,' 'anticipated,' 'believe,' 'will,' 'plans', and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea's current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control, our ability to manufacture sufficient commercial product, competition from approved treatments for HCV, the timeline for the completion of the strategic alternatives review process is unknown and there can be no assurance that the process will result in any particular outcome; dependence on the success of Atea's most advanced product candidates, in particular the combination of bemnifosbuvir and ruzasvir for the treatment of HCV; as well as the other important factors discussed under the caption 'Risk Factors' in Atea's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC's website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing Atea's views as of any date subsequent to the date of this press release.
Contacts
Jonae BarnesSVP, Investor Relations and Corporate Communications617-818-2985barnes.jonae@ateapharma.com
Joyce AllaireLifeSci AdvisorsJallaire@lifesciadvisors.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
CHARLEBOIS: Why matcha may be the next pumpkin spice
If you're a matcha drinker, brace yourself — prices are likely heading up, and TikTok may be to blame. What began as a traditional Japanese tea used in ceremonial settings has rapidly become a global wellness staple. Canada is no exception. Fuelled by social media and a surge in health-conscious consumer habits, matcha has gone mainstream. The Canadian market alone was valued at about $300 million in 2024, projected to reach $375 million by 2025 and nearly double to $700 million by 2035, according to Market Research Future. That represents a compound annual growth rate of approximately 7% over the next decade. Today, matcha is found not only in lattes but in smoothies, baked goods, energy bars, and even cosmetics. Its rise reflects a broader trend in Canadian food culture: The growing appeal of global ingredients that promise both functionality and indulgence. But matcha comes with a key economic constraint — supply. The production process is uniquely labour-intensive and deeply artisanal. Shade-grown, hand-picked, steamed, and stone-ground, authentic matcha — particularly from Japan's Uji region or parts of China — is difficult to industrialize. Canada, due to climate, cannot grow matcha domestically, meaning demand must be met through imports. The market's tightness leaves it exposed to price volatility as interest surges. Already, we're seeing the effects. Ceremonial-grade matcha that sells for roughly $28 per 100 grams in Japan can retail for as much as $120 in Canada — a markup exceeding 300%. Even culinary-grade matcha, which typically costs $5 to $14 in Japan, often doubles in price on Canadian shelves. As demand continues to grow, especially for premium varieties, prices could climb by another 30-40% in the coming years. There's also concern over authenticity. As matcha's profile rises, so too does the presence of lower-quality substitutes — powders that resemble matcha in colour but lack its nutritional properties and distinctive taste profile. Consumers may not always know the difference until they've overpaid. Cafes and restaurants are already reporting supply challenges, and many are struggling to keep pace with customer expectations. This isn't a passing inconvenience — it's an early sign of a demand-driven imbalance that may persist. Unlike fleeting trends like celery juice or butter boards, matcha's growth is supported by habit formation. Its caffeine content, antioxidant profile, and calming effects appeal especially to Millennials and Gen Z consumers looking for a healthier, more stable alternative to coffee. The fact that the industry — not just consumers — is embracing matcha also signals staying power. In many ways, matcha is positioned similarly to pumpkin spice two decades ago — only this time, with the added push of social media. For traditional coffee drinkers, there may be a silver lining. As matcha draws more market share, coffee demand may stabilize. That's welcome news after a year in which retail coffee prices rose 25%, according to Statistics Canada. In short, matcha is no longer niche. It's a case study in how consumer health trends, social media, and global trade dynamics can converge to reshape what — and how — we drink. If you're a coffee drinker, you might want to start promoting matcha yourself. Your wallet could thank you.
Yahoo
40 minutes ago
- Yahoo
Which Cryptocurrency Is More Likely to Be a Millionaire Maker? XRP vs. Cardano
XRP and Cardano might both grow significantly in the coming years. XRP's primary appeal is its strong association with institutional capital. Cardano's dedicated and active developer base could prove to be a major asset. 10 stocks we like better than XRP › XRP (CRYPTO: XRP) and Cardano (CRYPTO: ADA) have both been pitched as potential fast tracks to building up a hoard of seven figures. While it's generally not appropriate for serious investors to make purchases in the hopes of making millions overnight, over a long enough timescale, with enough diligent investment and the right asset selected, it is indeed possible. Between these two coins, both are well known, liquid, and still nowhere near their prior all‑time highs. That combination tempts bargain hunters. But price alone never mints millionaires, even in crypto; it's necessary to have a real set of fundamentals that'll drive a large influx of new capital even after a large amount has already shown up and stuck around. Let's examine which of these two actually has a credible shot at compounding long enough to turn persistent dollar‑cost averaging (DCA) into life‑changing gains. Let's start with some cold back-of-the-napkin arithmetic. XRP changes hands at about $2.19 today. A $10,000 position would need roughly a 100x gain to reach $1 million, at which point the coin's market cap would be roughly $11 trillion. For Cardano, it'd require a future market cap of around $2.3 trillion. Those numbers are long shots for both, but which chain has the better odds? Utility is a good starting proxy. On June 15, the XRP Ledger (XRPL) processed 5.1 million transactions in a single day, breaching its former records. That speaks directly to its core use case, which is to make cross-border transactions cheaper and faster than they would be using legacy technologies. High volume is a clear sign that its target user base, which is to say, institutional investors, are at least to some degree utilizing the chain for what it was intended to do. In contrast, Cardano lately averages closer to 50,000 daily transactions. It isn't precisely clear who the chain's target users are meant to be, but regardless of who it is, they do not appear to be actually using the chain very much at all in the grand scheme of things. That means it is less likely to grow rapidly. XRP also has an edge when it comes to competing in growth markets, like real‑world‑asset (RWA) tokenization. XRPL already hosts roughly $160 million in tokenized bonds, treasuries, and other off‑chain assets. Per some estimates, the tokenized asset market could grow from $0.6 trillion this year to reach $18.9 trillion by 2033. If XRP keeps compounding its early share of that pie, a pathway to triple‑digit gains exists. But Cardano has no comparable wedge into the same megatrend right now -- and, quite concerningly, it isn't actually exposed to any other trending growth segments either. Tech development is a major part of each coin's potential to make investors into millionaires. Once again, XRP takes the win. Ripple, the business that issues XRP, has spent 2025 adding tools that its core customer base actually wants. Ripple's developer summit this month unveiled identity‑layer upgrades that bake know‑your‑customer (KYC) regulatory compliance into the protocol, which is an existential requirement for large asset managers. Cardano, unfortunately, remains heavy on research papers and light on production traffic. Hydra, its long‑promised layer‑2 (L2) scaling system, is still in bug‑fix mode after recent security checks. Meanwhile, daily active wallet addresses hover near 24,000 -- far from being a user base of inspiring size. The chain's entire fee haul is less than $8,000 per day. Those metrics would be respectable for a start-up network, but they are tepid for a 9‑year‑old project. Developer activity is the lone area where Cardano shines, as in early 2025, it ranked among the top three chains in terms of updates pushed. Those high commit counts show some momentum, yet code is only valuable when users need what is being built, which is the main problem with the chain. Until Cardano's decentralized finance (DeFi) features become must‑have features for a defined audience, its robust research culture may not translate into price appreciation, and so far, it hasn't. For investors, the takeaway is clear. XRP is already solving paying customers' problems and charging fees to do so. Cardano is still refining the pitch. XRP is the coin that is more likely to make investors richer, but it probably won't deliver the eye-popping returns overnight that are necessary to make millionaires. Still, if the goal is to choose the stronger long‑term compounding machine, XRP currently offers better odds. Its growing transaction flow, embedded regulatory compliance features, and head start in the swelling RWA market create tangible revenue streams that can support higher valuations. Separately, Cardano remains an interesting technology play, and its staunch community plus academic rigor may yet pay off. For now, though, owning the coin is a wager that the team will eventually find a killer use case that drives non‑speculative demand. That might happen, but until it does, it is an investment thesis in search of evidence, not a smart place to put your capital. Before you buy stock in XRP, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and XRP wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends XRP. The Motley Fool has a disclosure policy. Which Cryptocurrency Is More Likely to Be a Millionaire Maker? XRP vs. Cardano was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Wyndham Hotels & Resorts, Elavon Partner to Revolutionize Payment Processing for 6,000+ Franchisees
Wyndham Hotels & Resorts Inc. (NYSE:WH) is one of the most undervalued US stocks according to analysts. On June 18, Elavon announced an expanded collaboration with Wyndham Hotels & Resorts. The partnership makes Elavon's Cloud Payments Interface/CPI available to 6,000+ Wyndham franchisees across the US and Canada. The initiative represents a significant advancement in hospitality payments processing. Elavon's CPI is a cloud-based solution that eliminates the need for hotels under Wyndham's 25 brands to purchase or maintain expensive on-site hardware for their property management systems. This reduces operational overhead, minimizes hardware-related security concerns, and enhances the simplicity and security of mobile check-in. A large hotel room with touches of luxury and hospitality in every corner. With CPI, Wyndham franchisees can benefit from scalable payment services, seamless integration with other cloud-based third-party software, and advanced encryption & tokenization technologies to safeguard transactions. Wyndham Hotels & Resorts Inc. (NYSE:WH) is a hotel franchisor in the US and internationally. Elavon is a global payments processor that is owned by US Bank (NYSE:USB), the fifth-largest US bank. While we acknowledge the potential of WH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
